The Beam NC Team?is focused, committed and proud to be part of a team that is dedicated?to driving forward our vision of providing lifelong cures to patients suffering from serious diseases #DaretoBeamNC #BeamTeam?
Beam Therapeutics
生物技术研究
Cambridge，Massachusetts 65,015 位关注者
Our vision is to provide life-long cures for patients suffering from serious diseases.
关于我们
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes. Our dream is to provide life-long cures for patients suffering from serious diseases. The Beam Team Is: ? A community of fearless innovators ? Rigorous and honest in our research ? Listening with open minds ? Committed to each other
- 网站
-
https://beamtx.com
Beam Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 501-1,000 人
- 总部
- Cambridge，Massachusetts
- 类型
- 上市公司
- 创立
- 2017
- 领域
- gene therapy、base editing、gene editing、precision medicines、CRISPR、CRISPR Cas9、genetic diseases、rare diseases、hematology、lipid nanoparticles、LNP、vector production、AAV、In vivo、ex vivo、Liver、mRNA Production、mRNA、DNA、RNA、Cas9、drug development、drug delivery、immunology、formulation development、virology、viral delivery、nanoparticles formulation、structural biology、cell biology、protein sciences和cell therapy
地点
-
主要
获取路线
238 Main St
US，Massachusetts，Cambridge，02142
Beam Therapeutics员工
动态
-
The #BeamTeam's?Brittany O'Donnell?is looking for a QC Microbiology Specialist with strong writing skills to join her team! This is a great opportunity to work at our state-of-the-art manufacturing facility and contribute to our vision of providing lifelong cures to patients suffering from serious diseases!?https://lnkd.in/e55qw_Y3
-
-
Our Chief Technology Officer Manmohan Singh, PhD, FAAPS, will be taking the stage as a panelist during the plenary keynote at this year's Bioprocessing Summit on August 21. He’ll join other industry leaders in a fireside chat to discuss the transformative potential of genetic medicines, including the technologies, tools and strategies to succeed in the clinic and commercially. Learn more about the conference here:?https://lnkd.in/eqYsS33 #CHIBioprocessingSummit?
-
-
Today, Beam reported second quarter 2024 financial results and provided updates across the company’s hematology and genetic disease franchises. Read the full press release here: https://lnkd.in/evwbtsJm #DaretoBeam #BeamTeam
-
-
This week we hosted an internal Speed Networking event in Cambridge and North Carolina with over 100 members of the Beam Team participating! The event aimed to: - Promote our mentorship program and value of hearing and sharing career stories. - Facilitate connections across Beam. - Practice talking about development.? ? Thanks to all of the #BeamTeam members who participated! #DaretoBeam
-
-
Last week, the #BeamTeam hosted PhD and Postdoc students from the University of Chicago’s MyChoice Program. The group had a chance to visit 10+ companies in the Boston area and while at Beam, they toured our Cambridge office, learned about the Beam story, and networked with members of the Beam Team! #DaretoBeam
-
-
Today, Beam announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase. Read the full press release here: https://lnkd.in/eS_xr8uJ
-
-
The #BeamTeam's Luis Brito, Vice President, LNP Platform, will be co-leading a workshop at the Controlled Release Society meeting on July 8th. Learn more about the Therapeutic Genome Editing Workshop: Tools, Delivery Systems, Prospects and Challenges here: https://lnkd.in/dTFxydBe
-
-
Last week, our North Carolina team celebrated #Pride with a tie-dye event and attended the OUT! Raleigh Pride! #DaretoBeam
-
-
Today, Beam announced the first patient was treated with BEAM-302, an investigational in vivo base editing medicine designed to precisely correct the underlying cause of severe alpha-1 antitrypsin deficiency (AATD), that is currently being evaluated in a Phase 1/2 clinical trial. Read the full press release here: https://lnkd.in/eUHQf7Bs #DaretoBeam #BeamTeam
-